Quince Therapeutics (QNCX) Other Non-Current Liabilities (2023 - 2026)
Quince Therapeutics (QNCX) posted quarterly Other Non-Current Liabilities of $1.2 million for Q1 2026, down 97.96% year-over-year from $58.6 million in Q1 2025, and down 23.82% quarter-over-quarter from $1.6 million in Q4 2025.
Quince Therapeutics (QNCX) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Quince Therapeutics' Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $1.2 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 97.96% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 97.96% YoY), while the FY2025 annual figure was $1.6 million, changed N/A from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1.2 million, down from $1.6 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $73.8 million in Q1 2024, with the low at $587000.0 in Q4 2023.
- The 4-year median for Other Non-Current Liabilities is $1.2 million (2026), against an average of $21.4 million.
- Peak annual rise in Other Non-Current Liabilities reached 22.33% in 2025, while the deepest fall reached 98.58% in 2025.
- Quince Therapeutics' Other Non-Current Liabilities stood at $587000.0 in 2023, then jumped by 9233.56% to $54.8 million in 2024, then plunged by 97.13% to $1.6 million in 2025, then declined by 23.82% to $1.2 million in 2026.
- Business Quant data shows QNCX's Other Non-Current Liabilities at $1.2 million in Q1 2026, $1.6 million in Q4 2025, and $778000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.20 Mn |
| Dec 31, 2025 | 1.57 Mn |
| Sep 30, 2025 | 778,000.00 |
| Jun 30, 2025 | 745,000.00 |
| Mar 31, 2025 | 58.62 Mn |
| Sep 30, 2024 | 54.79 Mn |
| Jun 30, 2024 | 609,000.00 |
| Mar 31, 2024 | 73.77 Mn |
| Dec 31, 2023 | 587,000.00 |